Nazopass (Oxymetazoline Hydrochloride)

Oxymetazoline Hydrochloride, the active ingredient in Nazopass, is a alpha-adrenergic agonist presented as a nasal decongestant for nasal use. It relieves nasal congestion associated with the common cold, sinusitis, and allergic rhinitis in adults and children.

GNH USA supplies Nazopass as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nazopass, an alpha‑adrenergic agonist nasal decongestant, is used to treat conditions that cause nasal blockage.

Common cold: reduces nasal congestion by vasoconstriction of nasal mucosal vessels. Sinusitis: alleviates blockage and improves sinus drainage. Allergic rhinitis: relieves nasal stuffiness caused by allergic inflammation.

Oxymetazoline Hydrochloride may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nasal irritation or burning sensation - Dryness of the nasal mucosa - Sneezing - Mild headache

Serious or Rare Side Effects: - Elevated blood pressure or hypertension - Tachycardia or irregular heart rhythm - Rebound nasal congestion (rhinitis medicamentosa) with prolonged use - Severe allergic reactions such as rash or angioedema

Use Nazopass with awareness of specific safety considerations.

Pregnancy: safety not established; consult a healthcare professional before use. Breastfeeding: unknown safety profile; use only if benefit outweighs potential risk. Age restrictions: not recommended for children under 6 years unless directed by a clinician. Concurrent nasal surgery: avoid use immediately before or after procedures involving the nasal passages. Avoid prolonged use: limit to 3‑5 days to prevent rebound congestion. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Oxymetazoline may interact with other sympathomimetic agents and cardiovascular drugs.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): may increase hypertensive response. - Other nasal decongestants: additive vasoconstriction risk. - Sympathomimetic drugs (e.g., ephedrine): may cause excessive cardiovascular stimulation.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: may reduce blood‑pressure‑lowering effect. - Beta‑blockers: may mask tachycardia signs. - Tricyclic antidepressants: potential additive cardiovascular effects.